Advertisement

The Market for Knowledge in Bio-Pharmaceuticals

  • Daisy Rhuguet
  • Christophe Silvy
Part of the Economics of Science, Technology and Innovation book series (ESTI, volume 22)

Abstract

The pharmaceutical industry can be simply defined as a gathering of all pharmaceutical product manufacturers. But in a wider sense, it encompasses large areas including the health care sector, whose objective is the development of `products of chemical or biological origin which are intended or purported to have a medicinal effect on man or animals and which are used especially for detection, prevention or treatment of diseases, injuries or disabilities’ (Roche, 1998).

Keywords

Pharmaceutical Industry Small Firm Knowledge Transfer Innovation Process Knowledge Exchange 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Antonelli C. The Evolution of the Industrial Organisation of the Production of Knowledge, 1998; S14S, Topical Paper STEP Group.Google Scholar
  2. Arora A, Gambardella A. The changing technology of technological change: general and abstract knowledge and the division of innovative labour. Research Policy; 1994, 23:523–47.CrossRefGoogle Scholar
  3. Arora A, Gambardella A. Complementary and external linkages: the strategies of the large firms in biotechnology. Journal of Industrial Economics, 1990, 4: 361–79.CrossRefGoogle Scholar
  4. Arora A, Gambardella A, Fosfuri A.: Markets for Technology (why do we see them, why don’t we see more of them and why we should care), Business Economics Series, Working Papers 1999,17, 523–33.Google Scholar
  5. Autio E. New technology-based firms in innovation networks synpletic and generative impacts. Research Policy, 1997; 26: 263–81.CrossRefGoogle Scholar
  6. Athreye S.: On Markets in Knowledge, ESRC, Working Paper, 1998, 83, Cambridge University.Google Scholar
  7. Böhme G, van der Daele W,. Die Geselschaftliche Orientierung des wissenchaftlichen Fortschrittes. in Starnberger Studien, 1978; 339–75.Google Scholar
  8. Cantley Mark, Dibner Mark. ` The Impact of Modern Biotechnology on R&D in the Life Sciences, and on Organisational Structure end the Management of Research in the Biopharmaceutical Industry: Concepts and measurements.’ In Part II: Biotechnology, Medical Innovation and the Economy: The Key Relationships. OECD (DSTI/STP/BIO(98)8/Final), 1998.Google Scholar
  9. Caves R, Whinston M, Hurwitz M, Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry: An Exploratory Analysis. Brooking Papers: Microeconomics, 1991,Mars.Google Scholar
  10. Cohen W.M, Levinthal O.A. Absorptive Capacity: a New Perspective on Learning and Innovation, Administrative Science Quarterly, 1990; 35: 128–152.CrossRefGoogle Scholar
  11. Darby M, Zucker L.G. Present at Biotechnological Revolution: Transformation of technological Identity For a Large Incumbent Pharmaceutical Firm, Research Policy,1997; 26: 429–447.CrossRefGoogle Scholar
  12. Dosi Giovanni. Technical Change and Economic Theory. London: Pinter Publishers, 1988.Google Scholar
  13. Dosi G. Technological Paradigms and Technological Trajectories: A suggested Interpretation of the Determinants and Directions of Technical Change. Research Policy, 11: 147–162.Google Scholar
  14. Drews Jürgen. Intent and Coincidence in Drug Research: The Impact of Biotechnology. Basel: Editiones Roche, 1996.Google Scholar
  15. Drews Jürgen. In Quest of Tomorrow’s Medecines, New York: Springer-Verlag, 1998.Google Scholar
  16. European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Industry in Figures. EFPIA: 1999.Google Scholar
  17. Finch S. Building the Compagny’s Portfolio. Financial Times Pharmaceuticals.1999, décember.Google Scholar
  18. Grabowski H. An Andlysis of US International Competitivness in Pharmaceuticals, Managerial and Decision Economics, 1989, spring, 27–33.Google Scholar
  19. Howells J. Research and Technology Outsourcing, CRIC Discussion Paper, 1997,6.Google Scholar
  20. Kühn Thomas. The Structure of Scientific Revolution. Chicago: Second ed. University Press, 1970.Google Scholar
  21. Mc.Kelvey. Discontinuities in Genetic Engineering for Pharmaceuticals? Firm Jumps and Lock-in Systems of innovation. Technology Analysis and strategic management,1996; 8, 2: 107–16.CrossRefGoogle Scholar
  22. Nelson Richard, Winter Sidney. An Evolutionary Theory of Economic Change. Cambridge MA: Harvard University Press, 1982.Google Scholar
  23. OECD. Biotechnology: International Trends and Perspectives 1982 Pharmaceutiques OnLine.http://www.pharmaceutiques.com.Google Scholar
  24. Pharmaceutical Research & Manufacturers of America. Pharmaceuticals Industry Profile. PhRMA reports: 1999 and 2000 available onhttp://www.phrma.org..
  25. Pisano Gary. -The Development Factory. Unlocking the Potential of Innovation Process, Boston: Harvard Business School Press, 1997.Google Scholar
  26. Pisano G. The Governance of Innovation: Vertical Integration and Collaborative Arrangements in The Biotechnology Industry, Research Policy; 1991,20: 237–251.CrossRefGoogle Scholar
  27. Roche. The Pocket Roche. Basel: F.Hoffrnann-La Roche, 1998.Google Scholar
  28. Ronchi E. `The Cycle of Innovation’. In Part II: Biotechnology, Medical Innovation and the Economy: The Key Relationships OECD (DSTI/STPBIO(98)8/Final), 1998.Google Scholar
  29. Ronchi E. Biotechnology and the Revolution in Health Care and Pharmaceuticals: The Science and the Technology. STI Review, 1996, 19.Google Scholar
  30. Sapienza A. R&D Collaboration as a Global Competitive Tactic: Biotechnology and the Ethical Pharmaceutical Industry. R&D Management; 1989, 19, 4: 285–295.CrossRefGoogle Scholar
  31. Saviotti P.P. ` Industrial Structure and the Dynamics of Knowledge Generation in Biotechnology.’ In Biotechnology and Comparative Advantage. Europe’s Firms and the Challenge, Senker J, ed. Cheltenham: Edward Elgar Publishing, 1998.Google Scholar
  32. Senker J. Biotechnology and Comparative Advantage. Europe’s Firms and the Challenge. Cheltenham: Edward Elgar Publishing, 1998.Google Scholar
  33. Shan W, Walker G, Kogut B. Interfirm Cooperation and Startup Innovation in the Biotechnology Industry. Strategic Management Journal; 1994, 15: 387–394.CrossRefGoogle Scholar
  34. Sharp M. The Science of Nations: Multinationals and American Biotechnology, STEEP discussion paper, SPRU,1996,28.Google Scholar
  35. Stephan P. The Economics of Science. Journal of Economic Litterature; 1996,34, 3, September, 1199–235.Google Scholar
  36. Tapon F, Thong M. Are Research Collaborations an Effective Strategy for Pharmaceutical Firms? An Empirical Study: 1988–1995, Working Paper, University of Guelph: june 1999.Google Scholar
  37. Teece D.J. Capturing Value from Knowledge Assets: The new Economy, Markets for Know-How, and Intangible Assets. California Management Review, 1998, 40, 3, 55–79.CrossRefGoogle Scholar
  38. Teece D.J. Profiting from technological innovation, Research Policy, 15, 6: 285–305.Google Scholar
  39. Tushman M.L, Anderson P. Technological Discontinuities and Organizational Environments, Administrative Science Quarterly, 31, 3: 439–465.Google Scholar
  40. Weinman N. Grands Groupes Pharmaceutiques Mondiaux: Une Nouvelle Approche de la Santé., France: Ministére de I’Economie, des Finances et de l’Industrie, décembre 1997.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Daisy Rhuguet
    • 1
  • Christophe Silvy
    • 1
  1. 1.CEFI-CNRS, Aix-en-ProvenceUniversitéde la MéditerranéeFrance

Personalised recommendations